Malignant lipogenesis defined by (11)C-acetate PET/CT predicts prostate cancer-specific survival in patients with biochemical relapse after prostatectomy.
Malignant de novo lipogenesis is strongly linked to the aggressiveness of prostate cancer (PCa) under experimental conditions. (11)C-Acetate PET/CT is a potential noninvasive biomarker of malignant lipogenesis in PCa, but its prognostic value is not known. The objective of this study was to analyse (11)C-acetate PET/CT image metrics in relation to survival.
All patients undergoing (11)C-acetate PET/CT in one university hospital from 2005 to 2011 due to PSA relapse after previous prostatectomy were retrospectively evaluated. Two groups of patients were compared: those who died from PCa and those who were censored. All previously reported findings of local recurrence, regional or distal lymph node metastases and bone metastases were counted and evaluated regarding (11)C-acetate uptake intensity (SUVmax) and tumour volume. Total tumour volume and total lipogenic activity (TLA, summed SUVmax??TV) were calculated. Survival analysis in the entire study population was followed by Cox proportional hazards ratio (HR) analysis.
A total of 121 patients were included, and 22 PCa-specific deaths were recorded. The mean PSA level at the time of PET was 2.69???4.35?ng/mL. The median follow-up of the study population was 79???28?months. PET identified at least one PCa lesion in 53?% of patients. Five-year PCa-specific survival after PET was 80?% and 100?% in patients with a positive and a negative PET scan, respectively (p?